CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

(1) PROPOSED CANCELLATION OF THE BOARD OF SUPERVISORS AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE RULES OF PROCEDURES
(2) PROPOSED AMENDMENTS TO THE CORPORATE GOVERNANCE RULES
(3) RESIGNATION OF DIRECTORS
AND
(4) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

CanSino Biologics Inc. (the "**Company**") held the ninth meeting of the third session of the board (the "**Board**") of directors (the "**Directors**") on October 27, 2025, to consider and approve, among other things, (i) the proposed cancellation of the board of supervisors of the Company (the "**Board of Supervisors**") and amendments to the articles of association of the Company (the "**Articles of Association**") and the rules of procedure for the general meeting of the shareholders of the Company (the "**Shareholders**") and the rules of procedure of Board of Directors (collectively, the "**Rules of Procedures**"); (ii) the proposed amendments to certain corporate governance rules; and (iii) the proposed appointment of independent non-executive Directors.

PROPOSED CANCELLATION OF THE BOARD OF SUPERVISORS AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE RULES OF PROCEDURES

The Board hereby announces that, on October 27, 2025, the Board considered and approved, among other matters, the resolutions on the cancellation of the Board of Supervisors and the corresponding amendments to the Articles of Association.

In accordance with the Company Law of the People's Republic of China (the "**Company Law**"), the Transitional Period Arrangements for the Implementation of the Rules of the Supporting Systems of the New Company Law (《關於新<公司法>配套制度規則實施相關過渡期安排》), and other relevant laws and regulations, and taking into consideration the Company's actual circumstances and operational needs, the Company proposes to cancel the Board of Supervisors, with the audit committee under the Board exercising the relevant powers and functions of the Board of Supervisors as stipulated in the Company Law.

In light of the above, the Board proposes to make amendments to the Articles of Association to remove any provisions that become obsolete due to the cancellation of the Board of Supervisors, to ensure compliance with the Company Law and related amendments made consequentially thereto.

To further enhance the Company's standard of corporate governance and standardized operations, and in accordance with the latest provisions of the Company Law and the Guidelines for Articles of Association of Listed Companies (《上市公司章程指引》), and other relevant laws, administrative regulations and normative documents, and taking into consideration the proposed cancellation of the Board of Supervisor, the Company proposed to amend the Articles of Association and the Rules of Procedures.

The proposed cancellation of the Board of Supervisors and amendments to the Articles of Association and the Rules of Procedures are subject to the approval of the Shareholders at an extraordinary general meeting (the "**EGM**") by way of special resolutions. Upon the cancellation of the Board of Supervisors, the rules of reference of the Board of Supervisors, as well as the positions of its chairman and members, will automatically cease.

PROPOSED AMENDMENTS TO CORPORATE GOVERNANCE RULES

To further enhance the Company's corporate governance structure, promote standardized operations, and protect the legitimate rights and interests of the Shareholders and investors, the Company proposed to amend certain corporate governance rules in accordance with the relevant laws and the Articles of Association, taking into consideration the Company's actual circumstances.

The corporate governance policies proposed to be amended include, among others (i) Management Policy for Raised Funds (《募集資金管理制度》), (ii) Management Policy for Related Party Transactions (《關聯交易管理制度》), (iii) Decision-making Policy for External Guarantees (《對外擔保決策制度》), (iv) Management Policy for External Investments (《對外投資管理制度》), (v) Terms of Reference for Independent Non-Executive Directors (《獨立非執行董事工作制度》), (vi) Information Disclosure Management Policy (《信息披露管理規定》), (vii) Investor Relations Management Policy (《投資者關係管理制度》), (viii) Insider Information Registration Policy (《內幕信息知情人登記管理制度》), (ix) Working Rules for the General Manager (《總經理工作細則》), (x) Working Rules for the Board Secretary (《董事會秘書工作制度》), (xi) Management Policy on Preventing Misappropriation of the Company's Funds by Controlling Shareholders and Related Parties (《防範控股股東及關聯方佔用公司資金管理制度》), (xii) Terms of Reference of the Audit Committee (《董事會審計委員會工作細則》), (xiii) Terms of Reference of the Remuneration and Appraisal Committee (《董事會薪酬與考核委員會工作細則》), (xiv) Terms of Reference of the Nomination Committee (《董事會提名委員會工作細則》), (xv) Management Policy for Deferred and Exempted Information Disclosure (《信息披露暫緩與豁免管理制度》), (xvi) Internal Control Evaluation Policy (《內部控制評價制度》), and (xvii) Internal Audit Management Policy (《內部審計管理制度》).

The proposed amendments to: (i) the Management Policy for Raised Funds (《募集資金管理制度》), (ii) the Management Policy for Related Party Transactions (《關聯交易管理制度》), (iii) the Decision-making Policy for External Guarantees (《對外擔保決策制度》), (iv) the Management Policy for External Investments (《對外投資管理制度》), and (v) the Terms of Reference for Independent Non-Executive Directors (《獨立非執行董事工作制度》) are subject to the approval of the Shareholders at the EGM. The remaining amended corporate governance policies have become effective upon approval by the Board.

RESIGNATION OF DIRECTORS

The Board hereby announces that Mr. Shuifa GUI ("**Mr. GUI**") and Mr. Jianzhong LIU ("**Mr. LIU**") have tendered their resignations as independent non-executive Directors. Their resignations are due to the approaching expiry of their six-year terms of office as independent non-executive Directors.

Before the election of new independent non-executive Directors at the EGM, Mr. GUI and Mr. LIU will continue to perform their duties as independent non-executive Directors and members of the relevant Board committees in accordance with applicable laws, regulations and the Articles of Association.

Both Mr. GUI and Mr. LIU have confirmed that they have no disagreement with the Company and the Board, and there are no other matters relating to their resignations that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Shareholders.

The Board would like to take this opportunity to express its sincere appreciation to Mr. GUI and Mr. LIU for their valuable contributions to the Company during their tenure of office.

PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Board is pleased to announce that, Mr. Man CHO (左敏) ("**Mr. CHO**") and Ms. Xuefeng JI (紀雪峰) ("**Ms. JI**") have been nominated as candidates for independent non-executive Directors of the third session of the Board, subject to the approval of Shareholders at the EGM.

The biographies of Mr. CHO and Ms. JI are set out as follows:

Mr. Man CHO (左敏), born in May 1961, has been serving as a non-executive director of Alphamab Oncology (康寧傑瑞生物製藥) since October 2024, a company listed on the Stock Exchange (stock code: 9966). In addition, Mr. CHO has been an independent director of Luoxin Pharmaceutical Group Stock Co., Ltd. (羅欣藥業集團股份有限公司), a company listed on Shenzhen Stock Exchange (stock code: 002793) since July 2025. He has also been the chairman of Chengdu Haifeng Biotechnology Co., Ltd. (成都海楓生物科技有限公司) since July 2025. From June 2013 to June 2023, Mr. CHO served as an executive director and the president of Shanghai Pharmaceuticals Holding Co., Ltd. (上海醫藥集團股份有限公司), a company listed on Hong Kong Stock Exchange (stock code: 2607) and Shanghai Stock Exchange (stock code: 601607), and held directorships in certain of its subsidiaries, including a director of Shanghai Pharmaceuticals (HK) Investment Limited from August 2017 to August 2023, the chairman of Shanghai SPH Ruier Drugs Co., Ltd. (上海上藥睿爾藥品有限公司) from August 2020 to August 2023 and the chairman and president of Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd. (上海生物醫藥前沿產業創新中心有限公司) from September 2021 to August 2024. From September 2020 to September 2024, he served as the chairman of Shanghai Biomedical Industrial Equity Investment Fund Partnership (Limited Partnership) (上海生物醫藥產業股權投資基金合夥企業(有限合夥)). In his early career, Mr. CHO served as vice chairman and chief executive officer of the Wing Fat Printing Co., Ltd., vice president of China Resources Pharmaceutical Group Limited, deputy general manager of Sanjiu Enterprise Group, chairman and general manager of Sanjiu Economic Trading Co., Ltd. and Nine Stars Printing and Packaging Co., Ltd., vice director and head of sales department of Shenzhen South Pharmaceutical Factory, and head of transfusion medicine department, head of the drug injection department and pharmacist of Nanfang Hospital, First Military Medical University, Guangzhou, etc. Mr. CHO obtained a bachelor's degree in pharmacy from Sichuan University (formerly known as West China University of Medical Science) and a master's degree in management from the School of Management of Fudan University. As of the date of this announcement, Mr. CHO is interested in 61,000 H Shares.

Ms. JI Xuefeng (紀雪峰), born in May 1978, possessed over 10 years of experience in the legal field. Since November 2024, she has been a director of Tianjin Jincheng State-owned Capital Investment Operation Co., Ltd. (天津津誠國有資本投資運營有限公司). Since June 2024, she has been a director of Tianjin Binhai Culture Tourism Development Co., Ltd. (天津濱海文化旅遊發展有限公司). In addition, since June 2024, Ms. JI has been an independent non-executive director of Tianjin Jinran Public Utilities Company Limited (天津津燃公用事業股份有限公司) a company listed on the Stock Exchange (stock code: 1265). Since October 2023, she has been a director of Tianjin Bincheng Marine Culture Tourism Development Co., Ltd. (天津市濱城海洋文化旅遊發展有限公司). Since March 2023, she has been an independent director of Northern International Trust Co., Ltd. (北方國際信託股份有限公司). Her primary practice areas include corporate and commercial law, international and domestic investment/finance, restructuring, merger and acquisitions, real estate and construction, finance, and government legal counsel. Since January 2019, she has been a senior partner and director at Beijing Anli (Tianjin) Partners (北京安理(天津)律師事務所). Ms. JI was awarded the title of "The Belt and Road Initiative and Compliance Road Top Ten Lawyers" in December 2019. From 2016 to 2018, Ms. JI served as a senior partner at Dacheng (Tianjin) Law Firm (北京大成(天津)律師事務所). Ms. JI is currently a vice-director of Tianjin Lawyers Association (天津市律師協會); a chief legal consultant expert of Tianjin Law Society (天津市法學會); a representative of Tianjin People's Congress (天津市人民代表大會); a representative of Heping District of Tianjin People's Congress (天津市和平區人民代表大會); an expert from the First Major Administrative Decision-Making Consultation and Argumentation of Tianjin Municipal People's Government (天津市人民政府); a coordinator of Spain Working Group by the Belt and Road International Lawyers Association (一帶一路律師聯盟西班牙工作組); one of the authors of the Legal Environment Report of the "Belt and Road" Countries of All China Lawyers Association (中華全國律師協會); a single supervisor of China Chamber of International of Commerce (Tianjin) (中國國際商會天津商會獨任監事); an expert in the Public-Private Partnership (PPP) Expert Database of Tianjin Municipal Finance Bureau (天津市財政局政府和社會資本合作(PPP)專家庫); an arbitrator of the Tianjin Arbitration Commission (天津仲裁委員會); an arbitrator of the Xi'an Arbitration Commission (西安仲裁委員會); a supervisor and member of the selection committee for the prosecutor of the Tianjin People's Procuratorate (天津市人民檢察院). Ms. JI graduated from Nankai University in China with a bachelor of arts, specializing in English in June 2001, and was conferred a law master degree by Nankai University in June 2004. She holds a Chinese lawyer's license.

The terms of office of Mr. CHO and Ms. JI shall commence from the date of approval at the EGM until the expiry of the term of the third session of the Board. They shall be eligible for re-election upon the expiry of their terms of office. The Company will enter into a service contract with each of Mr. CHO and Ms. JI upon approval at the EGM. Each of Mr. CHO and Ms. JI will receive an annual director's fee of RMB300,000 (pre-tax) from the Company in accordance with the remuneration plan for independent non-executive Directors of the third session of the Board of Directors approved by the Company on February 21, 2024.

As of the date of this announcement and as far as the Board of Directors is aware, save as disclosed above, each of Mr. CHO and Ms. JI has confirmed that (i) they do not hold directorship in other listed companies for the past three years, have no any other major appointment and professional qualifications nor any position in the Group for the last three years; (ii) they do not have any relationship with any Directors, supervisors, senior management or substantial or controlling Shareholders of the Company; and (iii) they do not have any interest in the shares of the Company or its associated corporation within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on the Stock Exchange, nor are there other matters regarding the appointment of Mr. CHO and Ms. JI as independent non-executive Directors which need to be brought to the attention of the Shareholders. Each of Mr. CHO and Ms. JI has not been subject to any penalty or punishment imposed by the China Securities Regulatory Commission or any other relevant authorities or stock exchanges.

GENERAL

A circular of the Company containing, among other things, detailed information of (i) the proposed cancellation of the Board of Supervisors and amendments to the Articles of Association and the Rules of Procedures; (ii) the proposed amendments to certain corporate governance rules; and (iii) the proposed appointment of independent non-executive Directors, will be despatched to the Shareholders in due course.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, October 27, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.